What Poinstan Treats: Main Uses and Benefits

Poinstan (Mefenamic Acid) is associated with symptomatic relief across key therapeutic domains involving symptoms related to physical discomfort, inflammation, and fever. The medication is indicated for both acute pain and the treatment of primary dysmenorrhea. This medicine is commonly used to help manage acute, short-term symptoms, as well as the recurrent manifestations of specific conditions.

The primary therapeutic applications include providing support for primary dysmenorrhea (severe menstrual cramps), menorrhagia (abnormally heavy menstrual bleeding), and easing mild to moderate acute pain such as that resulting from sprains, strains, dental procedures, or headaches. It is considered relevant in situations involving inflammatory or irritative processes, and may be part of symptomatic management for conditions such as osteoarthritis and rheumatoid arthritis, particularly when symptoms become more noticeable. Furthermore, it is applied to help address elevated body temperature (fever).

It is relevant in clinical settings that involve acute or unstable symptom patterns. The medication helps patients cope more steadily with difficult episodes by easing distress and supporting general well-being during symptomatic phases.

---

Quick Fact: Relief for Cyclical Discomfort

This medication is relevant for specific gynecological uses, helping manage the cyclical symptoms of pain and heavy menstruation.

Eligibility Map: Who can and cannot use Poinstan (Mefenamic Acid) — Official Regulatory Information

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults and adolescents 14 years of age are allowed for approved indications.
Populations for whom use is not recommended	Lactating (breastfeeding) women and women attempting to conceive [Source: SmPC].
Populations for whom use is contraindicated	Patients with known hypersensitivity to Mefenamic Acid or other NSAIDs [Source: FDA Label]. Patients with active gastrointestinal ulceration or chronic GI inflammation [Source: FDA Label, SmPC]. Patients with severe cardiac, renal, or hepatic failure [Source: SmPC]. Patients undergoing peri-operative pain treatment in the setting of CABG surgery [Source: FDA Label].
Age-related eligibility rules	Children under 14 years of age: Safety and efficacy have not been established for standard indications [Source: FDA Label]. Elderly/Geriatric Patients: Allowed, but at increased risk of serious consequences and must be used with caution [Source: FDA Label].
Condition-specific eligibility rules	Contraindicated in patients with Inflammatory Bowel Disease (IBD) [Source: SmPC]. Contraindicated for patients with pre-existing renal disease or significantly impaired renal function [Source: FDA Label].
Pregnancy eligibility status	Third Trimester Pregnancy (30 weeks gestation) is contraindicated [Source: FDA Label]. Use should be avoided after 20 weeks gestation [Source: FDA Label].

---

Resulting Eligibility Structure

Official eligibility statements:

• The medicine is contraindicated in patients with a history of allergic reactions to aspirin or other NSAIDs (cross-sensitivity).
• The medicine is contraindicated in cases of active gastrointestinal ulceration or severe organ failure (renal, hepatic, or cardiac).
• Safety and efficacy have not been established for use in pediatric patients under 14 years of age for standard indications.
• Use is not recommended for lactating women due to the potential for adverse effects in the infant.

Connection to the overall eligibility profile: Official regulatory documents define who can and cannot use this medicine by establishing formal contraindications for populations with specific disease states, such as active gastrointestinal ulceration or severe organ failure. Eligibility is also strictly limited by age thresholds and physiological status, with use being prohibited during late pregnancy and categorized as not established for young children. This structure ensures that only patient groups whose baseline health status is deemed acceptable under regulatory risk assessments are eligible for treatment.

Poinstan Interactions with other medicines and products

Poinstan (mefenamic acid) is a Non-Steroidal Anti-Inflammatory Drug (NSAID) and carries a significant risk of interacting with several other medications, primarily by affecting blood clotting, blood pressure control, and renal function.

Interacting Product Category	Key Interaction Outcomes	Regulatory Status
Anticoagulants (e.g., warfarin) and Anti-platelet agents (e.g., aspirin)	Increased risk of serious bleeding and hemorrhage. The use with oral anticoagulants often requires close monitoring.	Avoid or Monitor Closely
Other NSAIDs and Aspirin (including low-dose)	Increased risk of serious gastrointestinal adverse events, including bleeding and ulceration. Poinstan may interfere with aspirin's anti-platelet effect.	Avoid Concomitant Use
Antihypertensives (e.g., ACE Inhibitors, Diuretics, ARBs, Beta-blockers)	Reduced blood pressure-lowering effect and an increased risk of renal impairment, particularly in the elderly or dehydrated.	Use with Caution/Monitor
Lithium and Methotrexate	Increased plasma levels of these drugs, raising the risk of toxicity (e.g., lithium toxicity, methotrexate toxicity), due to reduced renal clearance.	Monitor Closely
SSRI Antidepressants and Corticosteroids	Increased risk of serious gastrointestinal bleeding.	Use with Caution

Co-administration with antacids containing magnesium hydroxide may significantly increase mefenamic acid levels. The combination with Ciclosporin or Tacrolimus may increase the risk of nephrotoxicity. Mifepristone should not be taken with an NSAID for 8–12 days following its administration, as the NSAID may reduce its effect.

Poinstan's mechanism of action is defined by its ability to modulate key enzymatic and receptor systems that influence the body's eicosanoid and pyretic pathways.

---

Dual Modulation of Prostaglandin Pathways

The core mechanism involves the non-selective, reversible inhibition of the Cyclooxygenase (COX-1 and COX-2) enzymes. By blocking these primary targets, the drug interferes with the Arachidonic Acid Cascade, leading to a reduction in the cellular synthesis of prostaglandins ( PGE2). This action limits the chemical environment supporting inflammatory signaling and prevents the sensitization of peripheral nerve endings, thereby limiting the transmission of nociceptive signals.

---

Central and Receptor-Level Mechanisms

Beyond primary enzyme blockade, the molecule engages in secondary mechanistic activities. It is suggested to act as an antagonist at specific E-type Prostanoid (EP) receptors, which limits the downstream effects of existing PGE2 on target cells. Furthermore, potential modulation of GABA-A receptors in the Central Nervous System (CNS) influences central nervous system activity in nociceptive pathways. This dual action on peripheral and central signaling modulates nociceptive and pyretic pathways, impacting the physiological control of body temperature elevation.

---

Constraints on Homeostatic Pathways

A necessary mechanistic constraint is the simultaneous inhibition of COX-1, which produces prostaglandins required for physiological homeostasis, including regulation of gastric mucosal integrity and renal blood flow. This non-selective engagement with the constitutive enzyme is a functional consequence of the drug's mechanism of action.

Poinstan (Mefenamic Acid) is a medication exclusively administered via the oral route, available as capsules (250 mg), tablets (500 mg), and an oral suspension for systemic delivery. Standard administration protocols emphasize a short-term, acute usage pattern.

Official Administration Guidelines

Administration Scope	Detail
Route of administration:	Oral administration only.
Dosing schedule (Adults):	Initial Dose: 500 mg once, followed by a Maintenance Dose of 250 mg.
Timing in relation to meals:	Must be taken with food or milk, or with a full glass of water, to aid with proper use and tolerability.
Preparation requirements:	The oral suspension form must be shaken well before administration.
Age-group rules:	Generally not recommended for children under 14 for acute pain/dysmenorrhea. The lowest effective dose should be used for the shortest duration in older adults.

Use-Context and Duration Constraints

The frequency pattern is typically intermittent and as-needed (e.g., every six hours), with use often starting at the onset of symptoms for cyclical conditions. Therapy for acute pain is generally limited to 7 days, and use for primary dysmenorrhea is restricted to 2 to 3 days. This represents the standard protocol for short-course administration.

Research Evidence / Overview of Studies for Poinstan (Mefenamic Acid)

---

Evidence for Use in Primary Dysmenorrhea (Menstrual Cramps)

Research explores Poinstan's role in primary dysmenorrhea using short-term, randomized controlled trials (RCTs) and meta-analyses. These studies monitored adult and adolescent females experiencing painful menstrual symptoms, measuring outcomes related to pain intensity and duration. Findings describe patterns observed in reported pain scores and the need for rescue pain medication, as tracked against treatment over a few menstrual cycles. Evidence remains limited regarding the long-term effects of repeated use over many years.

Evidence for Acute Mild to Moderate Pain

The evidence relies on very short-term, single-dose, placebo-controlled RCTs, often using pain models like post-operative settings. Studies monitored responses over fixed time intervals, typically 4 to 6 hours, examining outcomes related to physical discomfort. Research describes patterns related to measured differences in immediate pain scores when assessed against placebo. Dedicated research characterizing efficacy for continuous treatment beyond 7 days in general acute pain settings is limited.

Evidence for Menorrhagia (Heavy Menstrual Bleeding)

Research includes RCTs and crossover trials that monitored responses in premenopausal women. Studies examined outcomes related to the objective quantification of Menstrual Blood Loss (MBL) volume. Findings describe patterns related to changes in MBL volume when assessed against non-NSAID treatments. However, sample sizes were modest in many trials, and long-term effects over multiple years are not fully established.

Long-term Studies and Durability of Effect

The majority of high-quality research on Poinstan, such as the RCTs for acute pain and dysmenorrhea, focuses on short-term symptom control. Consequently, long-term effects are not fully established through dedicated, multi-year clinical trials. The available evidence helps contextualize how patients reported their experience during acute or episodic changes, but not the results of continued usage over an extended period.

Key Research Gaps and Uncertainty

A significant limitation across most key indications is that follow-up durations were limited, restricting knowledge about long-term effects. Evidence quality varies across studies, particularly for chronic conditions like inflammatory management. Findings for complex patients or certain special populations (e.g., older adults) are often uncertain or lacking, as the results apply only to the populations studied.

Common questions about Poinstan (FAQ)

---

Q: How quickly does Poinstan start to work?

According to official product information, the medicine is rapidly absorbed after being taken by mouth. Studies indicate that it typically reaches its highest levels in the blood, known as peak plasma levels, about 1 to 4 hours after the initial oral dose is administered.

---

Q: How long does the effect of Poinstan last?

Official information regarding how the body processes the medicine indicates that the half-life—the time it takes for half the drug to be eliminated from the body—is approximately two hours. This figure is often referenced when establishing the recommended interval between doses, which is determined by a healthcare provider.

---

Q: Is it okay to take Poinstan every day for a long time?

Official regulatory labeling establishes strict limits on the duration of use. For treating general acute pain, therapy must not exceed 7 days, and for primary menstrual cramps (dysmenorrhea), use is generally limited to 2 to 3 days. Continuous long-term administration is not recommended due to the officially documented risk of serious side effects that increase with the duration of use.

---

Q: Can Poinstan affect my ability to drive or operate machines?

Official product information lists certain adverse reactions that may affect cognitive function, including feelings of dizziness, drowsiness, confusion, and vertigo. Official label information suggests caution, recommending individuals observe their personal response to the medicine before operating machinery or driving.

---

Q: Can Poinstan be taken with my blood pressure medication?

Official regulatory warnings note that this medicine may reduce the blood pressure-lowering effect of certain blood pressure drugs, such as diuretics and ACE inhibitors. Furthermore, the combination may increase the risk of renal impairment (kidney issues). The concurrent use of these medicines, however, typically necessitates close medical surveillance due to the potential for interaction.

---

Q: Can Poinstan be taken with alcohol?

While regulatory documents may not list a direct interaction, official warnings indicate that the use of alcohol is considered an added risk factor for serious gastrointestinal adverse events, such as bleeding or ulceration.

---

Q: Does Poinstan cause weight gain or loss?

Official adverse reaction reports and warnings mention that unusual weight gain can be a possible sign of more serious side effects, such as edema (fluid retention) or heart failure. Weight loss has also been described as a less common reported side effect.

---

Q: Can Poinstan affect sleep?

Official adverse reaction lists for this medicine include reports of both insomnia (trouble falling or staying asleep) and drowsiness. These effects relate to how the medicine influences the body's nervous system.

---

Q: Is there a risk of developing a serious allergic reaction to Poinstan?

Official warnings describe the risk of serious allergic reactions (hypersensitivity) to the medicine. These rare but serious reactions include anaphylaxis and severe skin conditions such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

---

Q: How is Poinstan processed or broken down by the body?

According to official pharmacokinetics data, the medicine is predominantly broken down (metabolized) in the liver by a specific enzyme called CYP2C9. After metabolism, the drug and its byproducts are then eliminated from the body via both the urine and the stool.

---

Q: What are the official guidelines regarding use in children?

Official regulatory documents indicate that the safety and efficacy of the medicine have not been established for children under 14 years of age for standard approved uses. Some regions may use specific oral suspension formulations for younger children under clinical guidance, where eligibility and appropriate use are determined by a healthcare professional.

---

Q: Is Poinstan available in different strengths?

Official product information confirms the medicine is available in several dosage forms. These include capsules, typically in a 250 mg strength, and tablets, often in a 500 mg strength, in addition to an oral suspension form.

---

Q: Are there generic versions of Poinstan available?

Official drug authority records confirm that generic versions of the medicine, which contain the active ingredient Mefenamic Acid, have been approved and are generally available in the market.

---

Q: Can Poinstan be used for toothache relief?

Official regulatory documents in certain regions list the medicine as an analgesic for the symptomatic relief of various forms of pain, which includes dental pain.

---

Q: How do doctors monitor patients who are on long-term Poinstan therapy?

Official documents advise that patients on prolonged therapy should be kept under regular medical observation. Monitoring focuses on checking for signs of potential liver dysfunction, the development of a rash, changes in blood cell count, or the onset of diarrhea.

---

Q: Is there a known antidote for Poinstan?

Official documentation for overdose treatment states that there is no specific antidote available for this medicine. Treatment for overdose focuses instead on supportive measures, such as administering activated charcoal and measures to empty the stomach.

---

Q: Are there any specific genetic factors that affect how Poinstan works for a person?

Official product information notes that the medicine is metabolized by a specific liver enzyme, CYP2C9. Individuals who are considered poor CYP2C9 metabolizers may have the drug stay in their system longer, potentially resulting in abnormally high plasma levels.

---

Q: Can Poinstan affect lab test results?

Official warnings indicate that the medicine may cause a false-positive reaction when performing a specific diazo tablet test for urinary bile. Additionally, it may prolong prothrombin time in individuals taking anticoagulant medicine, necessitating careful monitoring of that lab test.

---

Q: Has Poinstan been recalled recently?

Official public health warnings have been issued in certain regions regarding the purchase and use of counterfeit drug products that have been falsely labeled as containing Mefenamic Acid. It is generally advised that the product be obtained from legitimate and verified dispensing sources.

How to Store and Dispose of Poinstan (Mefenamic Acid)

Official regulatory documents define strict storage and disposal requirements for Poinstan to maintain product stability and safety.

Storage Conditions

Requirement	Details (from official label/SmPC)
Temperature	Do not store above 25 C (controlled room temperature).
Protection	Keep in the original package and protect from moisture, heat, and direct sunlight.
Child Safety	Store locked up, out of the sight and reach of children.
Stability	Labeled shelf-life is 5 years for blister packs and 3 years for bottles.

Disposal Instructions

To dispose of unused or expired Poinstan, official guidance recommends using a drug take-back location or a mail-back envelope.

If a take-back option is unavailable, the drug should be removed from its packaging, mixed with an undesirable substance (e.g., used coffee grounds or dirt), sealed in a plastic container, and placed in the household trash. Do not flush the medicine down a toilet or pour it down a drain, and ensure the drug does not enter waterways or soil.